Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» immuno-oncology
immuno-oncology
Merck expands Mass. reach with Torque cancer collaboration
Bizjournals
Wed, 02/20/19 - 10:09 am
Torque
Merck
Keytruda
immuno-oncology
TRQ-1501
Chinese Immuno-Oncology Company to Raise $282 Million Via Hong Kong IPO
CP Wire
Mon, 02/18/19 - 11:21 am
CStone Pharmaceuticals
IPOs
China
Hong Kong
immuno-oncology
Sorrento and Yuhan Secure $40 Million for Immuno-Oncology Joint Venture
CP Wire
Tue, 02/12/19 - 10:02 am
Sorrento Therapeutics
Yuhan
ImmuneOncia
immuno-oncology
Sorrento and Yuhan Secure $40 Million for Immuno-Oncology Joint Venture
Tue, 02/12/19 - 09:55 am
Sorrento Therapeutics
Yuhan
ImmuneOncia
immuno-oncology
3SBio gains Verseau's macrophage checkpoint modulators for cancer
BioCentury
Tue, 02/12/19 - 09:36 am
3SBio
Verseau
macrophages
immuno-oncology
Another Immuno-Oncology Company, Another $90+ Million IPO
CP Wire
Mon, 02/4/19 - 10:59 pm
Harpoon Therapeutics
IPOs
immuno-oncology
Another Immuno-Oncology Company, Another $90+ Million IPO
Mon, 02/4/19 - 10:56 pm
Harpoon Therapeutics
IPOs
immuno-oncology
Immuno-Oncology Company Plans $92 Million IPO
CP Wire
Sun, 02/3/19 - 12:53 pm
TCR2 Therapeutics
immuno-oncology
IPOs
Immuno-Oncology Company Plans $92 Million IPO
Sat, 02/2/19 - 03:05 pm
TCR2 Therapeutics
immuno-oncology
IPOs
Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal Regarding its Immuno-oncology Candidate, VE800
CP Wire
Thu, 01/24/19 - 10:46 am
Vedanta Biosciences
VE800
immuno-oncology
microbiome
Vedanta Biosciences Publishes Seminal Research in Leading Scientific Journal Regarding its Immuno-oncology Candidate, VE800
Thu, 01/24/19 - 12:19 am
Vedanta Biosciences
VE800
immuno-oncology
microbiome
Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-partnered I/O drug
Endpoints
Thu, 01/17/19 - 12:01 am
Pfizer
PD-L1
cancer
immuno-oncology
Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact
Fierce Biotech
Mon, 01/7/19 - 10:10 am
Sanofi
Regeneron
immuno-oncology
AbbVie puts up $105M for Tizona's preclinical I/O drug
BioPharma Dive
Sat, 01/5/19 - 12:04 am
AbbVie
Tizona Therapeutics
TTX-030
immuno-oncology
Takeda builds arsenal for immuno-oncology research, creates cell therapy group
Endpoints
Thu, 01/3/19 - 11:43 pm
Takeda
immuno-oncology
cell therapy
Shire
Bristol-Myers to buy Celgene in industry-shaking $74B deal
Biopharma Dive
Thu, 01/3/19 - 09:50 am
M&A
Bristol-Myers Squibb
Celgene
immuno-oncology
Gilead Ends Year With Two Major Deals That Could Total More Than $3.125 Billion
BioSpace
Thu, 12/20/18 - 12:12 pm
Gilead Sciences
Agenus
Scholar Rock
immuno-oncology
AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial
Fierce Pharma
Thu, 12/13/18 - 10:07 pm
AstraZeneca
Imfinizi
clinical trials
immuno-oncology
The number of new I/O cancer drugs in the clinic continues to swell at an explosive pace -- offering new hope, fresh concerns
Endpoints
Thu, 11/29/18 - 09:49 am
immuno-oncology
Biotech Showcase Conference Reveals Six Therapeutic Areas Receiving the Most Investment Attention in 2019
CP Wire
Tue, 11/27/18 - 12:02 pm
biotech
Alzheimer's disease
NASH
RNA
gene therapy
immuno-oncology
orphan diseases
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »